Extracorporeal Blood Oxygenation and Ozonation, or EBOO, is mainly used in treating toxicity and chronic illnesses. Despite the high efficiency of major autohemotherapy (MAHT), also known as a 10-pass, they do not always provide the desired therapeutic effect, particularly in the treatment of infectious diseases for which it is desirable to subject a patient’s blood, as much as possible, to the treatment by ozone. An alternative method is Extracorporeal Blood Oxygenation – Ozonation (EBOO). The method combines the process of blood autotransfusion and its ozonation-oxygenation in the external circuit. Such an approach theoretically allows to ozonate up to half of the circulating blood volume in a single procedure. 

The International Society of Blood Purification recognizes EBOO as a method that can reduce viral load in patients with chronic hepatitis. A clinical trial has shown that the EBOO procedure was more effective in the treatment of peripheral artery disease than prostacyclin. In some studies, EBOO has shown clinical effectiveness: necrotizing fasciitis, severe peripheral arterial disease, coronary disease, cholesterol embolism, severe dyslipidemia, Madelung disease, and sudden deafness of vascular origin. There have been a number of cardiac surgeries with cardio-pulmonary bypass that have used EBOO during the operation.